Search

Search Results

• PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse¹, Marta Mosca², David A Isenberg³, Joan T Merrill⁴, Thomas Dörner⁵, Michelle Petri⁶, Edward M Vital^7|8, Eric F Morand⁹, Teri Jimenez¹⁰, Stephen Brookes¹¹, Janine Gaiha-Rohrbach¹², Christophe Martin¹³, Annette Nelde¹⁴, Christian Stach¹⁵ | ¹Duke University - Division of Rheumatology and Immunology Durham, USA; ²University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; ³University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; ⁴Oklahoma Medical Research Foundation Oklahoma City, USA; ⁵Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; ⁶Johns Hopkins University School of Medicine Baltimore, USA; ⁷University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; ⁸Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; ⁹Monash University - Centre for Inflammatory Diseases Melbourne, Australia; ¹⁰UCB Raleigh, USA; ¹¹Biogen Maidenhead, United Kingdom; ¹²Biogen Cambridge, USA; ¹³UCB Slough, United Kingdom; ¹⁴Biogen Baar, Switzerland; ¹⁵UCB Monheim am Rhein, Germany

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2318

  36

• PO:03:034 | Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and its Open-Label Extension Laura C Coates¹, M Elaine Husni², Mitsumasa Kishimoto³, Proton Rahman⁴, Philipp Sewerin⁵, Enrique R Soriano⁶, Barbara Ink⁷, Rajan Bajracharya⁷, Jason Coarse⁸, Philip J Mease⁹, Emanuela Mazzola¹⁰, Peter Nash¹¹ | ¹NDORMS, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford, United Kingdom; ²Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Cleveland, USA; ³Department of Nephrology and Rheumatology, Kyorin University School of Medicine Tokyo, Japan; ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland St. Johns, Canada; ⁵Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum Herne Germany; ⁶Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires Buenos Aires, Argentina; ⁷UCB Slough, United Kingdom; ⁸UCB Morrisville, USA; ⁹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington Seattle, USA; ¹⁰UCB Milan, Italy; ¹¹School of Medicine, Griffith University, Brisbane, Australia

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2290

  38

• PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a post-hoc summary of five phase 3 trials Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Hn Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶, Andrea Doria⁷ | ¹Centro Accademico Reumatologia, Dipartimento Scienze Cliniche Biologiche, Università degli Studi Torino, Osp. Mauriziano, Italy; ²Brigham and Women's Hospital, Divisione di Reumatologia, Infiammazione e Immunità, Harvard Medical School, Boston, MA, USA; ³Università Johannes Gutenberg di Mainz, Centro medico universitario, Germany; ⁴GSK, Immunologia Biostatistica London, UK; ⁵GSK, Global Medical Affairs Reumatologia, Dublin, Ireland; ⁶GSK, Global Medical Affairs Collegeville, PA, USA; ⁷Divisione di Reumatologia, Dipartimento di Medicina, Università di Padova, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2160

  149